In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee
Immune Biomarkers on the Radar—Comprehensive “Immunograms” for Multimodal Treatment Prediction
Correlation, Causation and Confounding—What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?
Lonely Driver ROS1
PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-Based Cohort Analysis
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients
ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer
Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib
Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas
BRAF V600E Mutation Is not Always Present as Expected! A Case Report of Lung and Thyroid Carcinomas
ALK Rearrangement Detected in a Focus of Pulmonary Atypical Adenomatous Hyperplasia
Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress
Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer
Cutaneous Toxicity Induced by Hibiscus Tea in a Patient Treated with Erlotinib
Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non–Small Cell Lung Cancer Patient
ALK-Rearranged Squamous Cell Carcinoma of the Lung Treated with Two Lines of ALK Inhibitors
Treatment of Bronchial Carcinoid Tumors: Is Surgery Really Necessary?
The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease
Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity